VAUGHAN, Ontario.—Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, has announced changes to its board of directors and reaffirmed its 2026 full-year guidance, which it raised on July 29, 2026. This action follows a request from Bausch Health Companies Inc., which has maintained a majority stake in Bausch + Lomb since its 2022 initial public offering and presently controls, either directly or via its wholly owned subsidiaries, roughly 87 percent of the company’s outstanding common shares, the announcement said.
Effective Aug. 5, 2026, the Bausch + Lomb board of directors appointed four new directors:
Thomas J. Appio, CEO, Bausch Health.
(Clockwise from top left) Thomas J. Appio, Robert Chersi, Laurence Paul, MD, and Barbara Trebbi.
Robert Chersi, founder of Chersi Services LLC, an executive director and professor at Pace University’s Center for Governance, Reporting & Regulation, and a seasoned director.
Laurence Paul, MD, co-founder and managing principal of Laurel Crown Partners, LLC, president of The Louis Berkman Company, minority owner of the Pittsburgh Steelers, and a director of Crew Knitwear, Vereco and Ampco-Pittsburgh Corporation.
Barbara Trebbi, president and co-CEO of Landry Trebbi Investment Corp., president of BXT Corp., and director of Acadian Asset Management Inc.
The new directors replace Steven Collis, Karen Ling, Thomas Ross and Andrew von Eschenbach, MD, each of whom has tendered their resignation to facilitate the new appointments. None of the resignations were the result of any disagreement with the company, according to the announcement.
“We welcome our new directors and appreciate the service and contributions of those departing the board,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Over the past several years, we’ve been very transparent about our strategy and the work required to build a stronger Bausch + Lomb. Today, we have exceptional talent across the company, momentum throughout our businesses and the strongest pipeline we’ve had in years. Our second-quarter performance reflects what this team has methodically built and the disciplined execution behind it, and our focus remains on executing our strategy and delivering long-term value.”
Bausch + Lomb is also reaffirming the full-year 2026 guidance, which it raised on July 29, 2026, including revenue of $5.440 billion to $5.540 billion and adjusted EBITDA excluding acquired IPR&D (non-GAAP)1 of $1.025 billion to $1.075 billion.
On July 29, Bausch + Lomb reported second-quarter revenue of $1.394 billion, an increase of 9 percent on a reported basis and 8 percent on a constant currency basis compared with the second quarter of 2025.
The company also announced that it is advancing a diversified pipeline across dry eye disease, surgical technologies, consumer eye health, contact lenses, retinal diseases, and emerging areas including AI and computational biology. This breadth is designed to support a sustained cadence of innovation and address important structural trends in eye health, including aging populations, rising childhood myopia and the growing prevalence of dry eye and retinal disease, the company noted.
